Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
11 2020
Historique:
received: 24 01 2020
revised: 06 07 2020
accepted: 19 09 2020
pubmed: 30 9 2020
medline: 9 6 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is an emerging opportunistic infection, but basic epidemiological data are lacking in most regions. We have investigated epidemiology and diagnostic and treatment practices in five EU countries (United Kingdom, Spain, Italy, France, Germany; EU5) and Japan. and methods: Annual prevalence in each country was established using a 2-round Delphi method in combination with a regional prevalence-estimation model that incorporated data obtained from a blinded physician screening survey (3154 physicians) and a real-world NTM-PD treating-physician/patient-chart observational study (619 physicians - 1429 patient charts). The annual prevalence of NTM-PD was estimated at 6.2/100,000 in the EU5 and 24.9/100,000 in Japan. Overall prevalence between the EU5 was comparable, while differences in regional prevalence were found to be pronounced in France and The United Kingdom. Regional differences were also found in Japan, with the majority of cases in Chubu and Kanto regions. This new methodology for obtaining often missing regional-level epidemiological data reveals dramatic variations in NTM-PD annual prevalence and helps pinpoint areas that may merit special preventative and treatment focus.

Sections du résumé

BACKGROUND
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is an emerging opportunistic infection, but basic epidemiological data are lacking in most regions. We have investigated epidemiology and diagnostic and treatment practices in five EU countries (United Kingdom, Spain, Italy, France, Germany; EU5) and Japan.
STUDY DESIGN
and methods: Annual prevalence in each country was established using a 2-round Delphi method in combination with a regional prevalence-estimation model that incorporated data obtained from a blinded physician screening survey (3154 physicians) and a real-world NTM-PD treating-physician/patient-chart observational study (619 physicians - 1429 patient charts).
RESULTS
The annual prevalence of NTM-PD was estimated at 6.2/100,000 in the EU5 and 24.9/100,000 in Japan. Overall prevalence between the EU5 was comparable, while differences in regional prevalence were found to be pronounced in France and The United Kingdom. Regional differences were also found in Japan, with the majority of cases in Chubu and Kanto regions.
CONCLUSION
This new methodology for obtaining often missing regional-level epidemiological data reveals dramatic variations in NTM-PD annual prevalence and helps pinpoint areas that may merit special preventative and treatment focus.

Identifiants

pubmed: 32992265
pii: S0954-6111(20)30304-8
doi: 10.1016/j.rmed.2020.106164
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106164

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Jodie A Schildkraut (JA)

Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: Jodie.Schildkraut@radboudumc.nl.

Jack Gallagher (J)

Clarity Pharma Research LLC, Spartanburg, SC, USA. Electronic address: Jgallagher@claritypharma.com.

Kozo Morimoto (K)

Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan. Electronic address: morimotok@fukujuji.org.

Christoph Lange (C)

Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany. Electronic address: clange@fz-borstel.de.

Charles Haworth (C)

Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge, UK. Electronic address: Charles.haworth@nhs.net.

R Andres Floto (RA)

Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge, UK. Electronic address: Arf27@cam.ac.uk.

Wouter Hoefsloot (W)

Radboud Center for Infectious Diseases, Department of Respiratory Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: Wouter.hoefsloot@radboudumc.nl.

David E Griffith (DE)

Department of Pulmonology, University of Texas Health Science Center at Tyler, Tyler, TX, USA. Electronic address: David.griffith@uthct.edu.

Dirk Wagner (D)

University Medical Center, Freiburg, Germany. Electronic address: Dirk.wagner@uniklinik-freiburg.de.

Jakko van Ingen (JV)

Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: Jakko.vanIngen@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH